Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
What the Q3 FY26 call signalled
2 of 3 strong
The short version
SPARC is prioritizing execution on two key clinical programs: MUC1 ADC in solid tumors and SCD-153 for alopecia areata, with early clinical proof-of-concept expected between late 2026 and 2027. SPARC is focusing on key clinical programs, especially their MUC1 ADC in solid tumors and the topical agent SCD-153 for alopecia areata, with expected early clinical proof of concept by the second half of 2027.
From Sun Pharma Advanced Research Company Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SPARC is prioritizing execution on two key clinical programs: MUC1 ADC in solid tumors and SCD-153 for alopecia areata, with early clinical proof-of-concept expected between late 2026 and 2027.
- Focused portfolio reshaping around oncology and immunology themes aims to unlock medium- to long-term value.
- Cost optimization efforts, including reduction of fixed costs by approximately $10 million annually, support scalable growth.
- Expansion of clinical programs, including addition of vitiligo trial and radio/chemosensitizer, will drive pipeline diversification.
- Collaboration with partners like Tiller Therapeutics to advance small molecule drug conjugates (SMDCs) supports potential new product launches.
2 more points from Sun Pharma Advanced Research Company Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sun Pharma Advanced Research Company Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SPARC has been focusing on aggressive portfolio building and scaling clinical programs.
- They strategically increased the India component of clinical development to reduce costs and enhance efficiency.
- Cost structure optimization has been significant, including reducing headcount (from 400+ to ~250) and lab centers (from 4 to 2).
- Outsourcing certain costly infrastructure capabilities to manage fixed costs.
- They are finalizing a funding plan to extend the cash runway to FY '28, aiming to complete this process in the first half of calendar year 2026.
2 more points from Sun Pharma Advanced Research Company Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Sun Pharma Advanced Research Company Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sun Pharma Advanced Research Company Ltd said on order book & pipeline — free account, 30 seconds.
Sun Pharma Advanced Research Company Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.9K Cr, net profit ₹1.8K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharma Advanced Research Company Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharma Advanced Research Company Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma Advanced Research Company Ltd Q3 FY26 results?
SPARC is prioritizing execution on two key clinical programs: MUC1 ADC in solid tumors and SCD-153 for alopecia areata, with early clinical proof-of-concept expected between late 2026 and 2027. SPARC is focusing on key clinical programs, especially their MUC1 ADC in solid tumors and the topical agent SCD-153 for alopecia areata, with expected early clinical proof of concept by the second half of 2027.
What is Sun Pharma Advanced Research Company Ltd share price analysis?
Sun Pharma Advanced Research Company Ltd currently shows a neutral. The stock trades at a P/E of 4.5 with a market cap of ₹7,086 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma Advanced Research Company Ltd planning capital expenditure?
SPARC has been focusing on aggressive portfolio building and scaling clinical programs.
Keep Sun Pharma Advanced Research Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.